Aurinia Pharmaceuticals Inc.
NASDAQ:AUPHBiotechnology
+$0.13 today
- Market cap
- $2.03B
- Beta
- 1.43
- P/E (TTM)
- 7.2
- EPS (TTM)
- $2.25
Volume 0.76M
Average 1.21M
AUPH EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Aurinia Pharmaceuticals Inc.NASDAQ: AUPH
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA grows, but more slowly than its trailing trend
Q2 FY2026 EBITDA of $54.57M rose 93.9% year over year, behind the +117.6% change in trailing-twelve-month EBITDA. Sequentially, it rose 9.7% from the prior quarter.
Context
- EBITDA amounted to 45.1% of revenue in FY2025, up 31.6 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of $178.47M (+39.7%) for the fiscal year ending Dec 2026, a slowdown from the +302.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $54.57M+9.7% QoQ
- Last fiscal yearDec 2025
- $127.76M+302.7% YoY
- LTMJun 2026
- $188.22M+117.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +93.9% | +17.7% | -76.2 pp |
| 1 year | +302.7% | +39.7% | -263.0 pp |
| 3-year CAGR | — | +23.0% | — |
| 5-year CAGR | +22.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 127.76M USD
- Year-over-year change
- +302.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 127.76M | +302.7% |
| FY2024 | 2024-12-31 | 31.73M | +150.3% |
| FY2023 | 2023-12-31 | (63.05M) | +39.2% |
| FY2022 | 2022-12-31 | (103.65M) | +41.6% |
| FY2021 | 2021-12-31 | (177.45M) | — |
EBITDA vs competitors
How AUPH compares with its peers on the latest reported figures
- AUPH's LTM Jun 2026 EBITDA of $188.22M is the highest of the 10 companies compared; the peer median is -$178.45M.
- Its year-over-year change of +117.6% is the highest of 9, against a peer median of -46.2%.
- EBITDA amounts to 60.4% of revenue for AUPH, versus a peer median of 2879.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $188.22M | +117.6% | — | 60.4% | |
| FY2025 | -$66.36M | -60.9% | — | 4915.2% | |
| LTM Mar 2026 | -$70.61M | -31.5% | — | 843.9% | |
EVMNEvommune, Inc. | LTM Mar 2026 | -$74.62M | — | — | 746.2% |
| LTM Mar 2026 | -$78.03M | -325.2% | — | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | -$178.45M | +0.1% | — | — |
| LTM Mar 2026 | -$245.81M | -69.1% | — | — | |
| LTM Jun 2026 | -$393.82M | -87.1% | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$442.87M | -9.5% | — | 5986.3% |
| LTM Jun 2026 | -$574.94M | +24.1% | — | — | |
| Peer median (excluding AUPH) | -$178.45M | -46.2% | — | 2879.6% | |
Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 45.61M | 134.03M | 175.51M | 235.13M | 283.06M |
| Cost of Revenue | 1.09M | 5.66M | 14.15M | 28.25M | 32.67M |
| Gross Profit | 44.51M | 128.37M | 161.37M | 206.89M | 250.39M |
| Gross Margin | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% |
| Research & Development | 51.14M | 44.99M | 49.64M | 20.79M | 32.51M |
| Selling, General & Admin | 171.44M | 196.37M | 195.04M | 172.03M | 101.79M |
| Operating Expenses | 225.25M | 239.84M | 253.06M | 211.57M | 145.48M |
| Depreciation & Amortization | 2.76M | 2.71M | 11.65M | 19.45M | 9.27M |
| EBITDA | (177.45M) | (103.65M) | (63.05M) | 31.73M | 127.76M |
| EBITDA Margin | -389.1% | -77.3% | -35.9% | 13.5% | 45.1% |
| Operating Income | (180.74M) | (111.47M) | (91.69M) | (4.69M) | 104.91M |
| Operating Margin | -396.3% | -83.2% | -52.2% | -2.0% | 37.1% |
| Interest Income | 529K | 5.12M | 17M | 16.97M | 13.57M |
| Interest Expense | 0 | 0 | 2.78M | 4.84M | 4.33M |
| Other Income / Expenses | 529K | 5.12M | 14.22M | 12.14M | 9.24M |
| Income Before Tax | (180.21M) | (106.35M) | (77.47M) | 7.45M | 114.16M |
| Pre-Tax Margin | -395.1% | -79.3% | -44.1% | 3.2% | 40.3% |
| Income Tax Expense | 760K | 1.83M | 551K | 1.7M | (173.05M) |
| Net Income | (180.97M) | (108.18M) | (78.02M) | 5.75M | 287.2M |
| Net Margin | -396.8% | -80.7% | -44.5% | 2.4% | 101.5% |
| EPS (Basic) | (1.40) | (0.76) | (0.54) | 0.04 | 2.14 |
| EPS (Diluted) | (1.40) | (0.76) | (0.54) | 0.04 | 2.07 |
| Weighted Avg Shares | 129.37M | 141.92M | 143.24M | 143.06M | 134.37M |
| Weighted Avg Shares (Diluted) | 129.37M | 141.92M | 143.24M | 146.19M | 138.7M |
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
Intrinsic Alpha fair value
Locked
Current Price
$15.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.